DXA Body Composition is Weakly Related to Blood Lipids, Blood Pressure, and Glucose in Firefighters

Current published data are inconclusive regarding whether DXA body composition measures of fat, lean, and regional fat mass are predictive of other CVD risk factors. PURPOSE: To determine if DXA measures can be used in a cardiovascular risk-predictive manner to indicate unhealthy levels of circulating lipoproteins in firefighters. METHODS: 256 male firefighters (age=35±10; ht=179±6.6 cm; wt=94±16 kg; BMI=29.9±4.6; fat mass=27.5±10.4 kg; lean mass=63±7.5 kg; gynoid%fat=28.7±6.5%; android%fat=36±11.3%; glucose=85±12.9 mg/dL; SBP=128±9 mmHg) underwent an annual cardiovascular risk profile screening and DXA scan; resting BP was also measured. We drew fasting blood samples, analyzed by a clinically certified lab, to determine glucose, HDL, LDL, total cholesterol, and triglycerides. Statistics included simple statistics and Pearson’s correlations. RESULTS:Table (*=p\u3c.01). CONCLUSIONS: Though the correlations were statistically significant, none of the DXA body composition measures explained a physiologically relevant portion of the variance in the CVD risk markers measured. We suggest that factors other than body fat contribute to lipid and blood pressure profiles in firefighters, a population at high risk for CVD

Predicting VO2max in Collegiate American-Style Football Athletes

Introduction: Maximal oxygen uptake (VO2max) is an important measurement for athletic performance. A common method of VO2max prediction is the Foster equation (MSSE, 1996). This equation produces accurate predictions in a normal population, however, significant difference has been noted between predicted and measured VO2max values when testing athletes. While other studies have produced new equations for athletes in general or even for soccer players, to our knowledge none have made one specifically for American-style football players. Purpose: The aim of this study is to develop an accurate VO2max prediction equation for collegiate American-style football athletes for testing on the treadmill with the standard Bruce protocol. Methods: Over 13 years, a total of 413 collegiate American football players (age: 18.5±1.15 yrs, height: 186.8±7.0 cm, weight 102.1±20.8 kg) were assessed for VO2max (Medical Graphics, Corp® Metabolic Cart) using the standard Bruce treadmill protocol. Linear regression analysis (JMP v. 12) determined which factor out of height, weight, or time spent on the test had a greater impact on VO2max. The linear regression analysis of the most significant factor against VO2max produced a prediction equation. Predicted VO2max was calculated using these data in both the Foster equation and this novel equation. Predicted values were compared to actual measured values with a t-test. α=0.05 for all statistical tests. Results: Of all the factors, time had the strongest relationship (p\u3c0.0001; r2=0.6464). The linear regression between VO2max and time produced a prediction equation: VO2max= -3.546 + 3.904(time in minutes). Both the Foster equation and this new equation were significantly and positively correlated with the actual VO2max values (Foster=0.805, New r=0.804). However, t-tests indicate that the Foster equation results were significantly different from the measured values (p=0.0007), and the new model’s results were not significantly different (p=1.0). Conclusion: The Foster equation is not a reliable predictor of VO2max as assessed on a treadmill in collegiate American-style football athletes. This new equation is more accurate to predict VO2max in this population

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Abstract BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .)

The Glial Differentiation Factor Nuclear Factor One B (Nfib) Induces Differentiation and Inhibits Growth of Glioblastoma.

International audienceThe molecule CD90 is a N-glycosylated, glycophosphatidylinositol anchored cell surface protein, originally described on thymocytes. CD90 has been considered as a surrogate marker for a variety of stem cells and has recently been reported on glioblastoma stem cells. CD90 is also expressed on T lymphocytes, endothelial cells, fibroblasts and neurons. The function of CD90 is not fully elucidated. CD90 has been involved in cell-cell and cell-matrix interactions, in neurite outgrowth, T cell activation and apoptosis. In this study, we confirmed the expression of CD90 on human glioblastoma stem-like cells from serum-free neurosphere cultures. We also observed RNA and protein CD90 expression on primary cell lines from FSC-containing culture (adherent cell lines) and on freshly prepared glioblastoma specimen. In order to study the function of CD90 on glioblastoma cells, we used a silencing strategy to decrease the expression of CD90 on the immortalized U251 cell line. We then compared the viability, the tumor growth and the migration property of the wild-type CD90+ U251 cells and CD90 down-regulated U251 clones. The decrease of CD90 expression did not affect the viability and the tumor growth of U251 cells. In contrast, down-regulation of CD90 mediated the decreased ability of tumor cell migration using both scratch wound healing and boyden chamber migration assays. Experiments are currently on going to test the effect of CD90 expression on tumorigenicity in mice models. In total, this study might lead to better understand the role of CD90 on the pathology in particular in term of tumor migration/invasion of human glioblastoma